

Changes in Megakaryocytes in Cases of Thrombocytopenia: Bone Marrow Aspiration and Biopsy Analysis

TEJINDER SINGH BHASIN, SONAM SHARMA, MRIDU MANJARI, RAHUL MANNAN, VANDANA KANSAL, MANISH CHANDEY, SANJAY PIPLANI

ABSTRACT

Background: Thrombocytopenia (platelet counts less than 150,000/ μ l) is commonly encountered in various hematological disorders including myelodysplastic syndromes as well as various non-myelodysplastic hematological conditions.

Aim: The present study was undertaken to calculate the prevalence of various conditions associated with thrombocytopenia and to record the megakaryocytic alterations in various cases of thrombocytopenia. Apart from this by means of statistical analysis it was tried to analyze whether a significant difference existed in megakaryocytic alteration noted in myelodysplastic versus non- myelodysplastic conditions.

Materials and Methods: A prospective series of 60 bone marrow aspirations along with concomitant bone marrow biopsies was conducted in a tertiary care centre catering to both urban as well as rural population in north India.

Statistical Analysis: The distribution of morphological changes in cases of non myelodysplastic conditions and myelodysplastic were compared using Chi-Square test. A p-value less than 0.05 was considered significant.

Results: The commonest cause of thrombocytopenia for which bone marrow examination was sought was dimorphic anaemia (18 cases, 30%), followed by myelodysplastic syndrome (06 cases, 10%) which was followed equally by acute lymphocytic leukemia and blast crisis of chronic myeloid leukemia (CML). Of all the non-MDS conditions apart from dimorphic anaemia, idiopathic thrombocytopenic purpura and chronic myeloid leukemia (blast crisis); megakaryocytic dysplastic forms were not noted in any other condition. In cases of myelodysplasia; dysplastic forms, bare megakaryocytic nuclei, hypogranular forms and micromegakaryocytes were seen. Comparison between frequencies of normal, high and low number of nuclear lobes among MDS (n=9) and non MDS (n=68) conditions were found to be statistically significant.

Conclusion: Further studies on the evaluation of megakaryocytic alteration and their contribution to thrombocytopenia can provide growing knowledge to the pathogenesis of numerous hematopoietic disorders that may identify broader clinical applications of the newer strategies to regulate platelet count and functioning.

Key Words: Megakaryocytes, Thrombocytopenia, Bone marrow

INTRODUCTION

Platelets are formed and released into the bloodstream by precursor cells called megakaryocytes (MK) that are derived from haematopoietic stem cells (HSCs), which evolve from the multipotential haemangioblast. Mature MKs give rise to circulating platelets by the acquisition of the cytoplasmic structural and functional characteristics necessary for platelet action [1,2], reaching cell sizes <50–100 microns in diameter and ploidy ranging up to 128 N [3,4]. Endoreduplication (polyploidisation) and expansion of cytoplasmic mass are the hallmarks of MK maturation [5]. The production of platelets by megakaryocytes requires an intricate series of remodeling events that result in the release of thousands of platelets from a single megakaryocyte. Abnormalities in this process can result in clinically significant disorders. A diversity of factors can contribute to anomalous platelet counts; one of these is inappropriate platelet production. Thrombocytopenia (platelet counts less than 150,000/ μ l) can lead to inadequate clot formation and increased risk of bleeding [6]. Thrombocytopenia is commonly encountered in various hematological disorders including myelodysplastic syndromes (MDS) as well as various non-myelodysplastic hematological conditions [7].

Various studies have highlighted the dysplastic morphology of megakaryocytes in thrombocytopenia associated with myelodysplastic syndromes (MDS). Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by bone marrow (BM) failure and increased risk of transformation to acute myeloid leukemia (AML) [8]. Megakaryocytic alterations have also been recorded in some bone marrow aspiration (BMA) series in non-myelodysplastic conditions.

The present study was undertaken to calculate the prevalence of various conditions associated with thrombocytopenia and to record the megakaryocytic alterations in various cases of thrombocytopenia; taking in account findings noted in both BMA as well as biopsy (BMB). Apart from this by means of statistical analysis it was tried to analyze whether a significant difference existed in megakaryocytic alteration noted in MDS versus non- MDS conditions.

MATERIALS AND METHODS

A prospective series of 60 bone marrow aspirations along with concomitant bone marrow biopsies was conducted in a tertiary care centre catering to both urban as well as rural population in north

India. All the cases of thrombocytopenia which were diagnosed on hematology analyzer (platelet count < 1, 50,000); confirmed subsequently by peripheral smears were taken up for the study. Both BMA and BMB were done from posterior superior iliac spine taking care of all the aseptic measures. Smears were drawn and air dried from the material aspirated and stained by May Grunwald Giemsa (MGG). The biopsy core obtained was fixed with 10 % buffered formaline overnight and then kept for decalcification for a period of 48 to 72 hours depending upon the hardness of the biopsy in 15 % EDTA solution. This was afterwards taken up for processing; 2-3 micron sections were cut and stained by hematoxylin and eosin and other special stains wherever deemed necessary.

Both the BMA and BMB slides were reviewed by 3 haematopathologists in a double blinded way. Findings concurring 2 out of 3 were taken as final and recorded in a systematic table. The clinical details, complete blood counts, and other relevant laboratory investigations were also obtained.

In the present study for scoring purposes the number and morphological changes were pre-defined before start of the study. The cases were defined according to the work done by Muhury M et al., [7] and broadly the cases were tabulated accordingly. The number of the megakaryocytes was considered as normal (one megakaryocyte per one to three low-power fields), increased (more than two megakaryocytes per low-power field) or decreased (one


megakaryocyte per five to ten low-power fields) [9].

The morphological changes of megakaryocytes that were studied included- nuclear segmentation, presence of immature forms, dysplastic forms, micromegakaryocytes, emperipolesis, platelet budding, cytoplasmic vacuolization, bare megakaryocytic nuclei and hypogranular forms. The presence of abnormal megakaryocytes which included the micromegakaryocytes, dysplastic forms, megakaryocytes with separated lobes and hypogranular forms were considered as dysmegakaryocytopoiesis [Table/Fig-1, 2].

All the findings noted in BMA were corroborated with findings in BMB. The number and morphology of the megakaryocytes in non-MDS related thrombocytopenia were assessed. Their significance was studied by comparing with the morphological changes in MDS. The distribution of morphological changes in cases of non-MDS conditions and MDS were compared using Chi-Square test. A p-value less than 0.05 was considered significant. The sensitivity and specificity for those morphological features is not calculated since the data type is not suitable for estimating sensitivities and specificities.

RESULTS

The commonest cause of thrombocytopenia for which bone marrow examination was sought was Dimorphic anaemia (18 cases, 30%). The second most common cause was MDS (06 cases,




[Table/Fig-1]: A: Collection of hypolobated megakaryocytes in bone marrow aspirate. (MGG 400 X)

B: Collection of hypolobated megakaryocytes in bone marrow biopsy section. (H & E 100X)

C: Highpower view of a hypolobated immature megakaryocyte in aspirate. (MGG 1000 X)

D: Highpower view of a hypolobated immature megakaryocyte in biopsy. (H & E 400 X)



[Table/Fig-2]: A: Multi nucleated dysplastic form of megakaryocyte in bone marrow aspirate. (MGG 400 X)

B: Cytoplasmic vacuolization of megakaryocytes noted in infection associated thrombocytopenia (IAT). (MGG 100 X)

C: Emperipolesis in megakaryocytes. (MGG 1000 X)

D: Hypogranular hypolobated megakaryocyte (MGG 400 X)

10%) which was followed equally by acute lymphocytic leukemia (ALL) and blast crisis of chronic myeloid leukemia (CML). Other causes recorded were multiple myeloma (MM), acute myeloid leukemia (AML), hairy cell leukemia (HCL), infection associated thrombocytopenia (IAT), myelofibrosis (MF), chronic lymphocytic leukemia (CLL), idiopathic thrombocytopenic purpura (ITP), lymphoma spillage, megaloblastic anemia, alastic anemia, hypersplenism and bone marrow necrosis [Table/Fig-3], [Table/Fig-4].

The changes in number and morphology of megakaryocytes in various hematological disorders were recorded [Table/Fig-5], [Table/Fig-6], [Table/Fig-7] and [Table/Fig-8]. There was an increase in the number of megakaryocytes in 4 cases of dimorphic anaemia and dysplastic forms were seen in 8 cases followed by hypogranular forms and cytoplasmic vacuolization in 6 and 5 cases respectively [Table/Fig-7]. Shows Megakaryocytic alterations observed in 4 commonest hematological disorders causing thrombocytopenia.

In cases of ALL; apart from hypogranular forms in 5 cases and emperipolesis(EMP) in 1 case, no major megakaryocytic alteration was detected.

Of all the non-MDS conditions apart from dimorphic anaemia, ITP and CML (blast crisis); megakaryocytic dysplastic forms were not noted in any other condition. On the other hand emperipolesis was noted in Dimorphic anaemia, IAT and ITP (2 cases each) and one case each in ALL and MF.

In cases of MDS, dysplastic forms, bare megakaryocytic nuclei, hypogranular forms and micromegakaryocytes were seen [Table/Fig-6] [Table/Fig-1 & 2]. The lobes in megakaryocytes were either Normal or reduced in most cases of MDS [Table/Fig-9]. Shows Comparison between frequencies of normal, high and low number of nuclear lobes among MDS (n=9) and non MDS (n=68) conditions.

DISCUSSION

MK and platelets, which are their progeny, are highly specialized cells that participate in hemostatic and inflammatory functions. Since each platelet lives only about 10 days, the platelet supply is continually renewed by production of new platelets from the maturation of MK [10].

Megakaryocytic proliferation and differentiation is typically abnormal in patients with myelodysplastic syndromes (MDS) [11]. In the present study a significant difference was noted regarding the MK number among MDS versus non MDS cases ($p=0.017$) with higher count more indicative of non MDS condition.

Conventionally a normal megakaryocyte has four to sixteen nuclear lobes and an immature megakaryocyte is defined as a young form of megakaryocyte having scant bluish cytoplasm and lacking lobulation of the nucleus which occupies almost all of the cell [6] [Table/Fig-8]. Comparison between frequencies of normal,


SN	Conditions	Number	Percentage
1	Dimorphic Anaemia	18	30.00
2	myelodysplastic syndromes (MDS)	06	10
3	Blast crisis Chronic Myeloid Leukemia (CML)	05	8.33
4	Acute lymphocytic leukemia (ALL)	05	8.33
5	Infection associated thrombocytopenia (IAT)	04	6.66
6	lymphocytic leukemia (CLL)	03	5.00
7	idiopathic thrombocytopenic purpura (ITP)	03	5.00
8	Megaloblastic Anaemia	03	5.00
9	multiple myeloma (MM)	02	3.33
10	acute myeloid leukemia (AML)	02	3.33
11	hairy cell leukemia (HCL)	02	3.33
12	Lymphoma spill	02	3.33
13	Aplastic Anaemia	01	1.66
14	hypersplenism (HS)	01	1.66
15	bone marrow necrosis (BMN)	01	1.66
16	HD (post chemotherapy)	01	1.66

[Table/Fig-3]: Condition associated with thrombocytopenia in present study

high and low number of nuclear lobes among MDS (n=9) & non MDS (n=68) conditions can be seen in [Table/Fig-9].

Dysplastic megakaryocytes were defined as those with single/multiple separate nuclei [Table/Fig-2]. Micromegakaryocytes were defined as megakaryocytes whose size was that of a large lymphocyte/monocyte and which had a single/bilobed nucleus. The megakaryocytes were considered to show platelet budding if there was budding of cytoplasmic processes from their surfaces. Hypogranular forms were defined as megakaryocytes with pale grey or water clear cytoplasm and sparse or no granules. The type of cell seen within the megakaryocyte in emperipolesis was also documented.

A shift to young, immature, less polyploid megakaryocytes and fewer mature platelet-producing megakaryocytes was the outstanding morphological feature noted in almost all the cases of ITP in the present study. Similar findings were observed by Houwerzijl et al., [9]. Deka L et al., observed that Megakaryocytes in cases of ITP showed a higher nuclear/cytoplasmic ratio ($p=0.021$), lower nuclear roundness factor ($p=0.04$) and lower nuclear contour ratio ($p=0.027$). Cellular circularity and compactness were significantly different in ITP as compared to non-ITP cases, indicating that the megakaryocytes were less round in ITP



[Table/Fig-4]: A: Bone marrow biopsy section showing cluserting of megakaryocytes in case of idiopathic thrombocytopenia (ITP). (H & E 400 X)
 B: Bone marrow biopsy section showing epithelioid cell granuloma in case of a patient with tuberculosis. (H & E 400 X)
 C: Bone marrow biopsy section showing increased fat spaces in aplastic anaemia. (H & E 400 X)
 D: Bone marrow biopsy section showing increased fibrosis in a case of myelofibrosis. (H & E 400 X)

SN	Conditions	Number/Low Power Field			
		Normal	Increased	Decreased	Absent
1	Dimorphic Anaemia	11	04	03	00
2	MDS	03	00	03	00
3	CML (Blast Crisis)	02	01	02	00
4	ALL	00	00	05	00
5	IAT	02	01	01	00
6	CLL	00	00	03	00
7	ITP	00	03	00	00
8	Megaloblastic Anaemia	01	01	01	00
9	MM	00	00	02	00
10	AML	01	00	01	00
11	HCL	00	00	02	00
12	Lymphoma spill	00	00	02	00
13	Aplastic Anaemia	00	00	01	00
14	HS	00	01	00	00
15	BMN	00	00	01	00
16	HD (post chemotherapy)	00	00	01	00

[Table/Fig-5]: Megakaryocytic alterations in different hematological disorders causing thrombocytopenia


subjects [12]. Dysplastic forms along with bare forms and micro-megakaryocytes were seen in half the cases of ITP.

Emperipolesis, seen in 02 cases with lymphocytes in all cases.


Conditions	IF	Dysp Forms	Bare forms	EMP	Budding	Cyto Vacuo	MM	Hypo forms	No. of nuclear lobes		
									N		
Dimorphic Anaemia	01	08	02	02	00	05	02	06	06	06	13
MDS	03	04	01	00	00	00	04	06	04	01	04
CML (Blast Crisis)	01	01	00	00	00	00	04	03	03	01	02
ALL	00	00	00	01	00	00	00	05	00	00	05
IAT	00	00	00	02	00	02	01	03	01	00	03
CLL	00	00	00	00	00	00	00	00	00	00	01
ITP	02	02	02	02	01	02	00	01	00	02	03
Megaloblastic Anaemia	00	00	01	00	00	00	01	01	02	02	02
MM	00	00	00	00	00	00	00	01	00	00	02
AML	00	00	01	00	00	00	00	01	00	00	02
HCL	00	00	00	00	00	00	00	00	02	00	02
Lymphoma spill	00	00	00	00	00	00	00	02	00	00	02
Aplastic Anaemia	00	00	00	00	00	00	00	01	00	00	01
HS	00	00	00	00	00	00	01	01	01	01	01
BMN	00	00	00	00	00	00	00	00	00	00	01
HD (post chemotherapy)	00	00	00	00	00	00	00	01	00	00	01

[Table/Fig-6]: Morphological changes in Megakaryocytes in various conditions

Rai et al reported Emperipolesis in 13 out of 19 cases (68.4%). In 5 cases, lymphocytes were seen within megakaryocytes, 4 cases showed lymphocytes and nucleated red blood cells (nRBCs), 2 cases showed lymphocytes, neutrophils and nRBCs, 2 cases showed nRBCs and one case showed lymphocytes and neutrophils within the megakaryocytes [13]. These findings correlated with the claim of Rozman C. and Vives Corrons JL [14] of a con-



[Table/Fig-7]: Etiology wise distribution of the patients presenting with thrombocytopenia (n=59)



[Table/Fig-8]: Megakaryocytic alterations observed in 4 commonest hematological disorders causing thrombocytopenia

siderable increase in megakaryocytic emperipolesis in idiopathic thrombocytopenic purpura (ITP).

The cytoplasmic vacuolization seen in half of the cases and this reflects an increased megakaryocyte turnover and indicates degenerative changes such as those of apoptosis and para-apoptosis [Table/Fig-3 & 5].

	MDS	High	Normal	Low
Chi-Square	45.208a	33.779a	19.753a	2.195a
df	1	1	1	1
Asymp. Sig.	.000	.000	.000	.138

[Table/Fig-9]: Comparison between frequencies of normal, high and low number of nuclear lobes among MDS (n=9) & non MDS (n=68) conditions.

a. 0 cells (.0%) have expected frequencies less than 5. The minimum expected cell frequency is 38.5.

Four case of IAT were observed in our study. Stasi R et al observed that Persistent thrombocytopenia may be the consequence of chronic infections with hepatitis C virus (HCV), human immunodeficiency virus (HIV), and Helicobacter pylori, and should be considered in the differential diagnosis of primary immune thrombocytopenia (ITP) [15]. Three cases of IAT had increased megakaryocytes as noted by Alter, Scanlon and Schechter [16]. According to them, the virus might directly damage the platelets or alter them to become antigenic, resulting in specific antiplatelet antibody formation. Alternatively, a virus-antivirus complex could precipitate on the platelets and damage them resulting in compensatory increase of megakaryocyte in the bone marrow. Other changes which were seen were emperipolesis, cytoplasmic vacuolization, micromegakaryocytes and hypogranular forms [Table/Fig-6].

In Dimorphic anemia, dysplastic forms were seen in eight cases. Wickramasinghe has also observed megakaryocytes with separation of nuclear lobes and nuclear fragments and attributed this to diminished DNA synthesis leading to nuclear maturation defect [17]. The finding of emperipolesis in anemia was in agreement with the observation of Tavassoli [18]. However, no platelet budding was observed in any of the cases.

A single case of hypersplenism showed hypogranular forms along with micro megakaryocytes with no dysplastic changes or nuclear budding seen. these changes are attributed to removal of platelets by increased pooling and by increased phagocytosis in the spleen (according to Diz-kucukkaya et al., [19].

All the 20 cases of leukemia-lymphoma syndrome showed decreased or absent megakaryocytes. This may be because of the autoantibodies against glycoprotein IIa-IIIb complex which have been demonstrated in patients with lymphoma. According to Lim and Ifthikharuddin, [20] along with immune-mediated platelet destruction, decreased platelet production when the marrow is involved by lymphoma, bone marrow suppression by chemotherapeutic agents and platelet sequestration in the spleen also contribute to thrombocytopenia in lymphoma. Other changes seen are individually tabulated including MF, granulomatous infection and aplastic anaemia [Table/Fig-4].

Further studies on the evaluation of megakaryocytic alteration and their contribution to thrombocytopenia can provide growing knowledge to the pathogenesis of numerous hematopoietic disorders that may identify broader clinical applications of the newer strategies to regulate platelet count and functioning.

REFERENCES

- [1] Patel SR, Hartwig JH & Italiano JE. The biogenesis of platelets from megakaryocyte proplatelets. *J Clin Invest.* 2005;115(12):3348-54.
- [2] Richardson JL., Shivdasani RA, Boers C, Hartwig JH & Italiano Jr, JE. Mechanisms of organelle transport and capture along proplatelets during platelet production. *Blood.*(2005): 106, 4066-75.
- [3] Tomer A, Harker LA & Burstein SA. Purification of human megakaryocytes by fluorescence-activated cell sorting. *Blood.* (1987): 70, 1735-42.
- [4] Tomer A, Harker LA & Burstein SA. Flow cytometric analysis of normal human megakaryocytes. *Blood.*(1988) : 71, 1244-52.
- [5] Deutsch VR and Tomer A. Megakaryocyte development and platelet production. *British Journal of Haematology.*(2006): 134, 453-66.
- [6] McKenzie SB, editor. Textbook of hematology. 2nd ed. *Pennsylvania.* Willaims and Wilkins; 1996.
- [7] Muhury M, Mathai AM, Rai S, Naik R, Pai MR, Sinha R. Megakaryocytic alterations in thrombocytopenia: a bone marrow aspiration study. *Indian J Pathol Microbiol.* 2009 Oct-Dec;52(4):490-04.
- [8] Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. *Hematology Am Soc Hematol Educ Program.* (2002), 136-61.
- [9] Houwerijl EJ, Blom NR, van der Want JJ, Esselink MT, Koornstra JJ, Smit JW, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. *Blood.* 2004;103:500-06.
- [10] Kaushansky K. The molecular mechanisms that control thrombopoiesis. *J Clin Invest.* (2005): 115(12): 3339-47.
- [11] Hofmann WK, Kalina U, Koschmieder S, Seipelt G, Hoelzer D, Ottmann OG. Defective megakaryocytic development in myelodysplastic syndromes. *Leuk Lymphoma.* 2000 Jun;38(1-2):13-9.
- [12] Deka L, Gupta S, Gupta R, Pant L, Kaur CJ, Singh S. Morphometric evaluation of megakaryocytes in bone marrow aspirates of immune-mediated thrombocytopenic purpura. *Platelets.* 2012 Apr 2. [Epub ahead of print].
- [13] Rai S, Sharma M, Muhary M, Naik R, Sinha R. Increased emperipolesis in megakaryocytes in a case of idiopathic thrombocytopenic purpura. *Indian J Pathol Microbiol.* 2009; 52 (3): 452-453.
- [14] Rozman C, Vives-Corrons JL. On alleged diagnostic significance of megakaryocytic phagocytosis (emperipolesis). *Br J Haematol.* 1998;48:510.
- [15] Stasi R, Willis F, Shannon MS, Gordon-Smith EC. Infectious causes of chronic immune thrombocytopenia. *Hematol Oncol Clin North Am.* 2009 Dec;23(6):1275-97.
- [16] Alter JH, Scanlon RT, Schechter PG. Thrombocytopenic purpura following vaccination with attenuated measles virus. *Am J Dis Child.* 1969;115:111-16.
- [17] Wickramasinghe SN. Morphology, biology and biochemistry of cobalamin- and folate- deficient bone marrow cells. *Baillieres Clin Haematol.* 1995;8:441-59.
- [18] Tavassoli M. Modulation of megakaryocyte emperipolesis by phlebotomy: megakaryocytes as a component of marrow-blood barrier. *Blood cells.* 1986;12:205-16.
- [19] Diz-Kucukkaya R, Gushiken FC, Lopez JA. Thrombocytopenia. In: Lichtman MA, Beutler E, Kipps T, Seligsohn U, Kaushansky K. *Prchal JT, editors. Williams Haematology.* 7th ed. USA: McGraw-Hill; 2006. p. 1749-8.
- [20] Lim SH, Ifthikharuddin JJ. Autoimmune thrombocytopenic purpura complicating lymphoproliferative disorders. *Leuk Lymphoma.* 1994;15:61-4.

AUTHOR(S):

1. Dr. Tejinder Singh Bhasin
2. Dr. Sonam Sharma
3. Dr. Mridu Manjari
4. Dr. Rahul Mannan
5. Dr. Vandana Kansal
6. Dr. Manish Chandey
7. Dr. Sanjay Piplani

PARTICULARS OF CONTRIBUTORS:

1. Associate Professor, Department of Pathology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India.
2. Resident, Department of Pathology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India.
3. Professor, Department of Pathology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India.
4. Associate Professor, Department of Pathology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India.
5. Resident, Department of Pathology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India.

6. Assistant Professor, Department of Pathology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India.
7. Associate Professor, Department of Pathology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Rahul Mannan,
Associate Professor, Department of Pathology,
9B, Chanderpuri, Taylor Road, Opposite
Gandhi Ground Amritsar, Punjab, India.
Phone: 9781613283
E-mail: rahulmannan@gmail.com

FINANCIAL OR OTHER COMPETING INTERESTS:

None.

Date of Submission: **Sep 13, 2012**
Date of Peer Review: **Sep 28, 2012**
Date of Acceptance: **Sep 29, 2012**
Date of Online Ahead of Print: **Jan 24, 2013**
Date of Publishing: **Mar 01, 2013**